266 results on '"Mainz, Jochen G."'
Search Results
2. Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and Calprotectin over one year of treatment with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged ≥12 years – The RECOVER study
3. ESPEN-ESPGHAN-ECFS guideline on nutrition care for cystic fibrosis
4. Cross-cultural adaptation and validation of the CFAbd-Score for gastrointestinal symptoms in patients with cystic fibrosis
5. Ultrashort echo time MRI of the lung in children and adolescents: comparison with non-enhanced computed tomography and standard post-contrast T1w MRI sequences
6. 8 Erkrankungen der oberen Atemwege
7. Chronic rhinosinusitis in people with CF, a rapidly changing field
8. A randomised crossover trial of tezacaftor-ivacaftor for gut dysfunction in cystic fibrosis with magnetic resonance imaging (MRI) outcomes: a pilot study.
9. Scoring Abdominal Symptoms in People with Cystic Fibrosis
10. Antigen specificity and cross-reactivity drive functionally diverse anti-Aspergillus fumigatus T cell responses in cystic fibrosis
11. Postprandial changes in gastrointestinal function and transit in cystic fibrosis assessed by Magnetic Resonance Imaging
12. Considerations for the use of inhaled antibiotics for Pseudomonas aeruginosa in people with cystic fibrosis receiving CFTR modulator therapy
13. S3-Leitlinie: Lungenerkrankung bei Mukoviszidose – Pseudomonas aeruginosa.
14. Prevalence of constipation in cystic fibrosis patients: a systematic review of observational studies
15. Erratum: S3-Leitlinie: Lungenerkrankung bei Mukoviszidose – Pseudomonas aeruginosa
16. ESPEN-ESPGHAN-ECFS guideline on nutrition care for cystic fibrosis
17. Caregiver Burden Due to Pulmonary Exacerbations in Patients with Cystic Fibrosis
18. A randomised crossover trial of tezacaftor-ivacaftor for gut dysfunction in cystic fibrosis with magnetic resonance imaging (MRI) outcomes.
19. 32. Jahrestagung der Arbeitsgemeinschaft für Pädiatrische Pneumologie und Allergologie (APPA) e. V.; 20. – 21. Oktober 2023, Brandenburg an der Havel
20. Validity and Reliability of a Novel Multimodal Questionnaire for the Assessment of Abdominal Symptoms in People with Cystic Fibrosis (CFAbd-Score)
21. Dynamics of abdominal symptoms during the start of a new therapy with Elexacaftor/Tezacaftor/Ivacaftor using the novel CFAbd-day2day questionnaire
22. Proliferative activity of antigen-specific CD154+ T cells against bacterial and fungal respiratory pathogens in cystic fibrosis decreases after initiation of highly effective CFTR modulator therapy
23. Corrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-Score
24. The Cystic Fibrosis Upper and Lower Airway Metagenome
25. Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis — Results of a multicenter, prospective, randomized, double-blind, controlled trial
26. Patient-reported outcomes in patients with cystic fibrosis with a G551D mutation on ivacaftor treatment: results from a cross-sectional study
27. Dynamics of abdominal symptoms during the start of a new therapy with elexacaftor/ tezacaftor/ivacaftor using the novel CFAbd-day2day questionnaire.
28. Protease–antiprotease imbalances differ between Cystic Fibrosis patients' upper and lower airway secretions
29. Divergent dynamics of inflammatory mediators and multiplex PCRs during airway infection in cystic fibrosis patients and healthy controls: Serial upper airway sampling by nasal lavage
30. Elevated Levels of Toxic Bile Acids in Serum of Cystic Fibrosis Patients with CFTR Mutations Causing Pancreatic Insufficiency
31. Sinonasal inhalation of dornase alfa administered by vibrating aerosol to cystic fibrosis patients: A double-blind placebo-controlled cross-over trial
32. Effects of ivacaftor on severely ill patients with cystic fibrosis carrying a G551D mutation
33. The potential of volatile organic compound analysis for pathogen detection and disease monitoring in patients with cystic fibrosis
34. Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score
35. Soluble inflammation markers in nasal lavage from CF patients and healthy controls
36. Diagnosing constipation in patients with cystic fibrosis applying ESPGHAN criteria
37. Abdominal Symptoms Assessed With the CFAbd-Score are Associated With Intestinal Inflammation in Patients With Cystic Fibrosis
38. Impact of timing of PERT on gastrointestinal symptoms in Danish children and adolescents with CF
39. Ultrashort echo time MRI of the lung in children and adolescents: comparison with non-enhanced computed tomography and standard post-contrast T1w MRI sequences
40. Intestinal Current Measurements Detect Activation of Mutant CFTR in Patients with Cystic Fibrosis with the G551D Mutation Treated with Ivacaftor
41. Management of chronic rhinosinusitis in CF
42. Extrapulmonary disease burden and impact of cystic fibrosis (CF) on productivity in people with CF (pwCF) aged >12 years not treated with CF transmembrane conductance regulator modulators (CFTRm): interim analysis (IA) of the HUBBLE study
43. Ivacaftor Reduces Inflammatory Mediators in Upper Airway Lining Fluid From Cystic Fibrosis Patients With a G551D Mutation: Serial Non- Invasive Home-Based Collection of Upper Airway Lining Fluid
44. Homozygous CFTR mutation M348K in a boy with respiratory symptoms and failure to thrive. Disease-causing mutation or benign alteration?
45. Pathogenesis and Management of Nasal Polyposis in Cystic Fibrosis
46. Non-invasive assessment of upper and lower airway infection and inflammation in CF patients
47. Cross-sectional study on bone density-related sonographic parameters in children with asthma: correlation to therapy with inhaled corticosteroids and disease severity
48. Ivacaftor Reduces Inflammatory Mediators in Upper Airway Lining Fluid From Cystic Fibrosis Patients With a G551D Mutation: Serial Non-Invasive Home-Based Collection of Upper Airway Lining Fluid
49. Audit of sweat chloride testing reveals analytical errors
50. Would it have happened without Christmas? Thoracic emphysema and allergic bronchopulmonary aspergillosis in a juvenile cystic fibrosis patient with the G551D mutation receiving ivacaftor
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.